Scholarlink

Background <p>Acute kidney injury (AKI) remains a significant complication following endovascular aneurysm repair (EVAR). Current diagnostic methods often detect kidney damage too late for effective intervention. This study evaluated proenkephalin A 119–159 as an early AKI biomarker after EVAR procedures, comparing point-of-care testing with the ELISA method.</p> Methods <p>Between April 2022 and June 2024, 68 patients undergoing elective EVAR were enrolled. Blood samples were collected preoperatively and for three consecutive postoperative days.</p> Results <p>AKI was diagnosed according to the KDIGO criteria, with proenkephalin A 119–159 measured via point-of-care (penKid) testing and laboratory ELISA method. AKI occurred in 18 patients (26.5%). penKid showed a superior diagnostic performance to ELISA, demonstrating moderate agreement with KDIGO criteria (Gwet’s <i>AC1</i> = 0.52, <i>p</i> &lt; .001). While penKid exhibited high sensitivity (80% day 1), specificity was moderate (51%). AKI patients had significantly higher median penKid levels (96.47&#xa0;pmol/L vs 63.01&#xa0;ng/mL, <i>p</i> = .001), longer hospital stays (12 vs 9&#xa0;days, <i>p</i> = .028), and lower 6-month survival (50% vs 88.1%, <i>p</i> = .006).</p> Conclusions <p>penKid testing shows promise as an early AKI biomarker following EVAR procedures, particularly for identifying low-risk AKI patients. However, its moderate specificity suggests it should complement existing clinical assessment tools rather than replace them. These findings support incorporating penKid monitoring into structured AKI care bundles for improved perioperative kidney outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Proenkephalin A 119–159 as an early biomarker of acute kidney injury in complex endovascular aortic repair: an explorative single-center cross-sectional study with the utilization of two measurement methods

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月4日

查看全文
  • Paulina Walczak-Wieteska,
  • Konrad Zuzda,
  • Jolanta Małyszko,
  • Paweł Andruszkiewicz

摘要

Background

Acute kidney injury (AKI) remains a significant complication following endovascular aneurysm repair (EVAR). Current diagnostic methods often detect kidney damage too late for effective intervention. This study evaluated proenkephalin A 119–159 as an early AKI biomarker after EVAR procedures, comparing point-of-care testing with the ELISA method.

Methods

Between April 2022 and June 2024, 68 patients undergoing elective EVAR were enrolled. Blood samples were collected preoperatively and for three consecutive postoperative days.

Results

AKI was diagnosed according to the KDIGO criteria, with proenkephalin A 119–159 measured via point-of-care (penKid) testing and laboratory ELISA method. AKI occurred in 18 patients (26.5%). penKid showed a superior diagnostic performance to ELISA, demonstrating moderate agreement with KDIGO criteria (Gwet’s AC1 = 0.52, p < .001). While penKid exhibited high sensitivity (80% day 1), specificity was moderate (51%). AKI patients had significantly higher median penKid levels (96.47 pmol/L vs 63.01 ng/mL, p = .001), longer hospital stays (12 vs 9 days, p = .028), and lower 6-month survival (50% vs 88.1%, p = .006).

Conclusions

penKid testing shows promise as an early AKI biomarker following EVAR procedures, particularly for identifying low-risk AKI patients. However, its moderate specificity suggests it should complement existing clinical assessment tools rather than replace them. These findings support incorporating penKid monitoring into structured AKI care bundles for improved perioperative kidney outcomes.